Effect on Cognitive Function of a Treatment With Aripiprazole

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of Schizophrenia
score of 2-6 in the CGI-S scale at basline
ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment

Exclusion criteria

women of child bearing potential
women pregnant or breast feeding
patients with a score of 0,-1 or 7
substance use

Treatment and study plan

Aripiprazole

Drug

Tablets, oral, 15 mg, once daily, 12 weeks.

Other names: Abilify

Primary outcomes

Clinical Global Impression scale at endpoint

Secondary outcomes

Change in Clinical Global Impression scale and cognition scales at endpoint

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Industry

Collaborators

Otsuka America Pharmaceutical

Registry information

Official study title

A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients

Important dates

Study start: 2005
Primary completion: 2006
Study completion: 2006
First posted: May 25, 2006
Registry last updated: Nov 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed